SCHEMBL5833076

SCHEMBL5833076

CS(=O)(=O)c1ccc(CC(=O)NCC2CN(Cc3cccc(Cl)c3)CCO2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD4 P21917 7/20 0.48
CCR3 P51677 1/20 0.47
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
MAPT P10636 1/20 0.43
SIGMAR1 Q99720 5/20 0.43
CYP1A2 P05177 2/20 0.42
CYP3A4 P08684 2/20 0.42
CYP2C9 P11712 2/20 0.42
LMNA P02545 1/20 0.42
HTR1A P08908 1/20 0.42
ADRA2A P08913 1/20 0.42
ADORA3 P0DMS8 1/20 0.42
ADRA2B P18089 1/20 0.42
HTR2C P28335 1/20 0.42
SLC6A4 P31645 1/20 0.42
CYP2C19 P33261 1/20 0.42
DRD3 P35462 1/20 0.42
HTR2B P41595 1/20 0.42
KCNH2 Q12809 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5832699 0.93 DRD4 (0.48) DRD4CCR3MEN1KMT2AMAPT
SCHEMBL4022549 0.90 CCR3 (0.57) DRD4CCR3MEN1KMT2ASIGMAR1
SCHEMBL4027488 0.90 CCR3 (0.57) DRD4CCR3MEN1KMT2ASIGMAR1
SCHEMBL4026470 0.90 CCR3 (0.57) DRD4CCR3MEN1KMT2ASIGMAR1
SCHEMBL5843280 0.90 DRD4 (0.47) DRD4CCR3MEN1KMT2AMAPT
SCHEMBL5832890 0.87 CCR3 (0.54) DRD4CCR3MEN1KMT2AMAPT
SCHEMBL5867264 0.87 CCR3 (0.54) DRD4CCR3MEN1KMT2AMAPT
SCHEMBL5867261 0.87 CCR3 (0.54) DRD4CCR3MEN1KMT2AMAPT
SCHEMBL4021803 0.86 CCR3 (0.59) DRD4CCR3SIGMAR1CYP1A2CYP3A4
SCHEMBL6201146 0.86 DRD4 (0.49) DRD4CCR3MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1324990-B1 MORPHOLIN-ACETAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES GLAXO GROUP LTD (GB) 2014-10-29 EP claimed
US-7101882-B2 Morpholin-acetamide derivatives for the treatment of inflammatory diseases GLAXO GROUP LIMITED (GB) 2006-09-05 US claimed
US-20040058923-A1 Morpholin-acetamide derivatives for the treatment of inflammatory diseases SMITHKLINE BEECHAM CORPORATION 2004-03-25 US claimed
EP-1324990-B1 MORPHOLIN-ACETAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES GLAXO GROUP LTD (GB) 2014-10-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058923-A1 Morpholin-acetamide derivatives for the treatment of inflammatory diseases CCR1, MALT1, REL DRD4 3922/4885CCR3 7/4885MEN1 2256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.